FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to novel compounds of the formula (I): wherein R1 means hydrogen atom (H) or (C1-C8)-alkyl; R2 means (C1-C8)-alkyl, -CH2-O-(C1-C8)-alkyl, -OH or -CH2OH; R2a means H; or R2 and R2a for in common -CH2-CH2-; R3 means halogen atom, perhalogenalkyl, -CN, -SR5, -NHR5, -N(R5)2, aryl or heteroaryl wherein indicated aryl can comprise optionally up to two substitutes chosen from (C1-C8)-alkyl, halogen atom, perhalogenalkyl and alkoxy-group, and indicated heteroaryl can comprise optionally up to two substitutes chosen from halogen atom and (C1-C8)-alkyl; R4 means H, halogen atom, perhalogenalkyl, -CN, -OR5, -SR5, -NHR5, -N(R5)2, -OH, aryl or heteroaryl wherein indicated aryl can comprise optionally up to two substitutes chosen from (C1-C8)-alkyl, halogen atom, perhalogenalkyl and alkoxy-group, and indicated heteroaryl can comprise optionally up to two substitutes chosen from halogen atom and (C1-C8)-alkyl; or R3 and R in common with atoms to which they are added can form 5- or 6-membered heterocyclic ring comprising one oxygen atom (O); each R5 means independently (C1-C8)-alkyl, (C2-C8)-alkenyl, aryl, heteroaryl, arylalkyl, alheteroarylalkyl, perhalogenalkyl or allyl; R6 means H or (C1-C8)-alkyl, or their pharmaceutically acceptable salts, solvates or hydrates under condition that if R6 differs from H then R4 can't mean H; if R1 and R2 mean methyl and R4 means H then R3 can't -NHR5 or -N(R5)2; if R1 and R2 mean methyl and R4 means H then R3 can't imidazole, substituted imidazole or imidazole derivative. Also, invention relates to a pharmaceutical composition used for modulation of 5-HT2C receptors, a method for modulation of 5-HT2C receptors, a method for prophylaxis or treatment of disorders of the central nervous system and obesity, a method for reducing food consumption in mammals, a method for inducing the satisfying sense in mammals and to a method for preparing the composition. Invention provides synthesis of novel compounds possessing useful biological properties and preparing pharmaceutical composition based on thereof.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
70 cl, 1 tbl, 57 ex
Title | Year | Author | Number |
---|---|---|---|
CONDENSED AZEPINE DERIVATIVES AS ANTIDIUTETIC AGENTS | 2001 |
|
RU2269517C2 |
BICYCLIC AGONISTS OF VASOPRESSIN | 2000 |
|
RU2254332C2 |
(3-CYCLOALKYL-2, 3, 4, 5 - TETRAHYDRO-1H-BENZO [d] AZEPIN-7-YLOXY) DERIVATIVES, USE THEREOF FOR INHIBITING H3 RECEPTORS, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD | 2003 |
|
RU2388752C2 |
CETP INHIBITORS | 2006 |
|
RU2513107C2 |
NEW BENZAZEPIN DERIVATIVES | 2003 |
|
RU2423353C1 |
COMPOUNDS | 2003 |
|
RU2327690C2 |
HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND THEIR USING | 2001 |
|
RU2289581C2 |
DERIVATIVES OF TETRAHYDROISOQUINOLINE, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR INHIBITION OF SYNAPTIC UPTAKE OF DOPAMINE AND TREATMENT METHOD | 2000 |
|
RU2293728C2 |
6-5 CONDENSED RINGS AS C5a INHIBITORS | 2018 |
|
RU2780338C2 |
MODULATORS OF ATP-BINDING CARTRIDGE TRANSPORTERS | 2005 |
|
RU2528046C2 |
Authors
Dates
2008-02-27—Published
2003-04-11—Filed